ABC (²¹²Pb-undisclosed)
Multiple Solid Tumors
DiscoveryEarly research
Key Facts
About ARTBIO
ARTBIO is pioneering a holistic approach to Alpha Radioligand Therapy (ART), combining a differentiated pipeline with proprietary isotope production and manufacturing capabilities. Founded in 2021 by the inventors of the first-ever metabolically targeted alpha therapy (Xofigo), the company is advancing multiple programs, with its lead candidate AB001 now in Phase 1/2 clinical trials for prostate cancer. Backed by a strong syndicate of top-tier life science investors, ARTBIO aims to unlock the superior efficacy and safety profile of alpha-emitting radioligands to treat a range of solid tumors.
View full company profileTherapeutic Areas
Other Multiple Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| BAY 1817080 | Bayer | Phase 1 |
| Zanzalintinib + nivolumab | Exelixis | Phase 1b/2 |
| Zanzalintinib + atezolizumab | Exelixis | Phase 1b/2 |
| XL309 | Exelixis | Phase 1 |
| XB010 | Exelixis | Phase 1 |
| XB628 | Exelixis | Phase 1 |
| XB371 | Exelixis | Phase 1 |
| ADU-1805 | Exelixis | Phase 1 |
| Multiple Preclinical Programs | Perspective Therapeutics | Preclinical |
| Pre-Targeting Platform | Perspective Therapeutics | Preclinical |
| VDC Platform | Aura Biosciences | Pre-clinical/Discovery |
| MGC026 | MacroGenics | Phase 1 |